Fang-Jen Wu1, Shiow-Yunn Sheu1, Herng-Ching Lin2, Shiu-Dong Chung3. 1. School of Pharmacy, Taipei Medical University, Taipei, Taiwan. 2. School of Medical Laboratory Sciences and Biotechnology, Taipei Medical University, Taipei, Taiwan; Sleep Research Center, Taipei Medical University Hospital, Taipei, Taiwan. 3. Sleep Research Center, Taipei Medical University Hospital, Taipei, Taiwan; Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, Ban Ciao, Taipei, Taiwan. Electronic address: chungshiudong@gmail.com.
Abstract
OBJECTIVE: To examine the relationship between the use of androgen deprivation therapy (ADT) and the subsequent risk of falls in men with prostate cancer (PC) by employing a population-based dataset. METHODS: We retrieved the study sample from the Taiwan Longitudinal Health Insurance Database 2005. We included 886 patients with PC who had received ADT as the study group, whereas 862 patients with PC who had not received ADT served as the comparison group. We then individually tracked each study patient for a 3-year period to identify those who subsequently received a diagnosis of a fall. We performed Cox proportional hazard regressions to calculate the hazard ratio (HR) and its corresponding 95% confidence interval (CI) for a fall during the 3-year follow-up period between these 2 groups. RESULTS: The incidence rates of falls per 1000 person-years were 13.37 (95% CI: 9.15~18.88) and 6.44 (95% CI: 3.61~10.63), respectively, for patients with PC who received ADT and those who did not receive ADT. Furthermore, the hazard ratio for a fall during the 3-year follow-up period for patients with PC who had received ADT was 1.95 (95% CI: 1.04~3.66, P = .037) compared to those who had not received ADT after censoring sampled patients who died during the 3-year follow-up period and adjusting for age, geographical location, monthly income, urbanization level, hypertension, diabetes, hyperlipidemia, coronary heart disease, Parkinson's disease, epilepsy, stroke, and mental illness. CONCLUSION: The present findings suggest that patients with PC who had received ADT had an increased risk of falls.
OBJECTIVE: To examine the relationship between the use of androgen deprivation therapy (ADT) and the subsequent risk of falls in men with prostate cancer (PC) by employing a population-based dataset. METHODS: We retrieved the study sample from the Taiwan Longitudinal Health Insurance Database 2005. We included 886 patients with PC who had received ADT as the study group, whereas 862 patients with PC who had not received ADT served as the comparison group. We then individually tracked each study patient for a 3-year period to identify those who subsequently received a diagnosis of a fall. We performed Cox proportional hazard regressions to calculate the hazard ratio (HR) and its corresponding 95% confidence interval (CI) for a fall during the 3-year follow-up period between these 2 groups. RESULTS: The incidence rates of falls per 1000 person-years were 13.37 (95% CI: 9.15~18.88) and 6.44 (95% CI: 3.61~10.63), respectively, for patients with PC who received ADT and those who did not receive ADT. Furthermore, the hazard ratio for a fall during the 3-year follow-up period for patients with PC who had received ADT was 1.95 (95% CI: 1.04~3.66, P = .037) compared to those who had not received ADT after censoring sampled patients who died during the 3-year follow-up period and adjusting for age, geographical location, monthly income, urbanization level, hypertension, diabetes, hyperlipidemia, coronary heart disease, Parkinson's disease, epilepsy, stroke, and mental illness. CONCLUSION: The present findings suggest that patients with PC who had received ADT had an increased risk of falls.
Authors: Kerri M Winters-Stone; Esther Moe; Julie N Graff; Nathan F Dieckmann; Sydnee Stoyles; Carolyn Borsch; Joshi J Alumkal; Christopher L Amling; Tomasz M Beer Journal: J Am Geriatr Soc Date: 2017-03-06 Impact factor: 5.562
Authors: A L Couderc; X Muracciole; E Nouguerede; D Rey; S Schneider; P Champsaur; E Lechevallier; L Lalys; P Villani Journal: J Nutr Health Aging Date: 2020 Impact factor: 4.075
Authors: Emma J Foster; Raphae S Barlas; Joao H Bettencourt-Silva; Allan B Clark; Anthony K Metcalf; Kristian M Bowles; John F Potter; Phyo K Myint Journal: Front Neurol Date: 2018-04-03 Impact factor: 4.003
Authors: Kerri M Winters-Stone; Fuzhong Li; Fay Horak; Nathan Dieckmann; Arthur Hung; Christopher Amling; Tomasz M Beer Journal: Trials Date: 2021-11-06 Impact factor: 2.279
Authors: T M Wildes; S Alibhai; S Sattar; K Haase; S Kuster; M Puts; S Spoelstra; C Bradley Journal: Support Care Cancer Date: 2020-07-16 Impact factor: 3.603